Shenzhen, China, 10 January, 2025 – MGI Tech Co., Ltd. (“MGI”), a company committed to building core tools and technologies that drive innovation in life science, proudly presents the ATOPlex Platform, a comprehensive multiplex PCR-based library preparation technology that is revolutionizing targeted sequencing. In the rapidly evolving field of genomics where precision and efficiency are paramount, ATOPlex Platform can perfectly match MGI’s automated systems，sequencing platforms and bioinformatics analysis system, providing a total solution to key challenges of sensitivity, accuracy, and operational simplicity in targeted sequencing. By streamlining workflows and elevating performance, the ATOPlex Platform not only empowers researchers and clinicians to focus on specific regions of interest with unparalleled precision; it opens new avenues for applications across diverse fields.

The heart of ATOPlex technology is MGI’s proprietary ultra-high plex PCR technology, which allows for exceptional performance in targeted sequencing. The innovative ultra-high plex PCR  workflow in one tube eliminates the need for multiple tube transfers, significantly reducing contamination risks and simplifying operational processes for ultimate efficiency. Moreover, ATOPlex’s ability to amplify target genes from minute samples – as few as 0.1 ng– as well as from crude samples such as blood spot lysates and bacterial culture medium underscores its reliability and flexibility.

Unlocking the Power of Targeted Sequencing

One of the core advantages of the ATOPlex technology lies in its novel primer design, which effectively mitigates primer dimerization – a common challenge found in ultra-high plex PCR due to the simultaneous use of thousands of primer pairs. Conventional methods often require separate reaction tubes for different primer sets targeting continuous gene regions. In contrast, the solution employs a proprietary single-tube PCR approach that minimizes dimer formation and non-specific amplification, enabling reliable detection of nearly 20,000 targets in a single reaction, making it an invaluable tool for researchers.

ATOPlex features a robust dUTP/UNG anti-contamination system to combat the critical issue of aerosol contamination. By replacing dTTP with dUTP in PCR reactions and treating amplified products containing uracil with uracil-DNA glycosylase (UNG), which degrades DNA with incorporated uracil, the platform effectively eliminates contamination while ensuring accurate results – an essential requirement in scientific and clinical research.

Furthermore, the ATOPlex Platform supports direct amplification from complex lysates without extensive DNA extraction processes, broadening the range of compatible sample types while simplifying workflows. With a detection limit as low as 0.1 ng, it adds to the user experience by offering extraordinary versatility, reducing turnaround time and lowering cost.

Lastly, ATOPlex’s user-friendly online primer design tool (ATOPlex.mgi-tech.com) empowers researchers to design custom panels based on their specific needs, whether for DNA or RNA targets. It supports a wide range of customization options – from 10 to 20,000× coverage – providing rapid feedback and downloadable primer sequences. For more complex projects, dedicated offline technical support from MGI ensures seamless execution and robust solutions.

Expanded a variety of sequencing applications

MGI's ATOPlex panel, capable of detecting SNPs, CNVs, STRs, and gene fusions, has suported a wide range of fields, including infectious disease, microbiology, oncology, food safety, agriculture, forensic genetics, and direct-to-consumer (DTC) genetic testing, etc.

MGI have a variety of panels that support the detection of Dengue virus, Monkeypox virus, Influenza virus, HIV, Mycobacterium tuberculosis and can detect eDNA. In medical diagnostics, it has facilitated the detection of cancer biomarkers and genetic mutations, facilitating early intervention and precision treatment strategies. In food safety, it has played a crucial role in monitoring pathogens and contaminants to ensure public health. The platform has also assisted the agricultural sector in breeding programs and the detection of plant pathogens, ultimately contributing to food security. Additionally, it has provided consumers with valuable insights into their genetic makeup by empowering DTC testing.

A Glimpse into the Future

MGI’s ATOPlex Multiplex PCR Platform represents new standards in targeted sequencing by offering researchers and clinicians a powerful, reliable, and flexible tool for genomic analysis. Its cost-effectiveness, high sensitivity, and adaptability are redefining the way sequencing data are generated and applied, and sequencing technologies utilized across industries.

Looking towards the future, MGI remains committed to innovation and excellence, with plans to further enhance the ATOPlex Platform to support CycloneSEQ long-read sequencing library preparation. This upcoming upgrade will expand the capabilities of targeted sequencing even further, driving groundbreaking research and clinical applications.

If you are interested in the ATOPlex panel from MGI, scan the code for consultation.